Spatially mapping the immune landscape of melanoma using imaging mass cytometry

Dan Moldoveanu(Montreal General Hospital), LeeAnn Ramsay(McGill University Health Centre), Mathieu Lajoie(McGill University Health Centre), Luke Anderson-Trocmé(McGill Genome Centre), Marine Lingrand(McGill University Health Centre), Diana Berry(McGill University Health Centre), Lucas J. M. Perus(McGill University Health Centre), Yuhong Wei(McGill University Health Centre), Cleber Moraes(McGill University Health Centre), Rached Alkallas(McGill University Health Centre), Shivshankari Rajkumar(McGill University Health Centre), Dongmei Zuo(McGill University Health Centre), Matthew Dankner(McGill University Health Centre), Eric Hongbo Xu(McGill University Health Centre), Nicholas Bertos(McGill University Health Centre), Hamed S. Najafabadi(McGill Genome Centre), Simon Gravel(McGill Genome Centre), Santiago Costantino(Hôpital Maisonneuve-Rosemont), Martin J. Richer(Indiana University School of Medicine), Amanda W. Lund(New York University), Sonia V. del Rincón(Jewish General Hospital), Alan Spatz(McGill University Health Centre), Wilson H. Miller(Jewish General Hospital), Rahima Jamal(Centre Hospitalier de l’Université de Montréal), Réjean Lapointe(Centre Hospitalier de l’Université de Montréal), Anne‐Marie Mes‐Masson(Centre Hospitalier de l’Université de Montréal), Simon Turcotte(Centre Hospitalier de l’Université de Montréal), Kevin Petrecca(Montreal Neurological Institute and Hospital), Sinziana Dumitra(Montreal General Hospital), Ari N. Meguerditchian(Montreal General Hospital), Keith Richardson(McGill University Health Centre), Francine Tremblay(Montreal General Hospital), Béatrice Wang(McGill University Health Centre), May Chergui(McGill University Health Centre), Marie‐Christine Guiot(Montreal Neurological Institute and Hospital), Kevin Watters(McGill University Health Centre), John Stagg(Centre Hospitalier de l’Université de Montréal), Daniela F. Quail(McGill University Health Centre), Catalin Mihalcioiu(McGill University Health Centre), Sarkis Meterissian(Montreal General Hospital), Ian R. Watson(McGill University Health Centre)
Science Immunology
April 1, 2022
Cited by 129

Abstract

Melanoma is an immunogenic cancer with a high response rate to immune checkpoint inhibitors (ICIs). It harbors a high mutation burden compared with other cancers and, as a result, has abundant tumor-infiltrating lymphocytes (TILs) within its microenvironment. However, understanding the complex interplay between the stroma, tumor cells, and distinct TIL subsets remains a substantial challenge in immune oncology. To properly study this interplay, quantifying spatial relationships of multiple cell types within the tumor microenvironment is crucial. To address this, we used cytometry time-of-flight (CyTOF) imaging mass cytometry (IMC) to simultaneously quantify the expression of 35 protein markers, characterizing the microenvironment of 5 benign nevi and 67 melanomas. We profiled more than 220,000 individual cells to identify melanoma, lymphocyte subsets, macrophage/monocyte, and stromal cell populations, allowing for in-depth spatial quantification of the melanoma microenvironment. We found that within pretreatment melanomas, the abundance of proliferating antigen-experienced cytotoxic T cells (CD8 + CD45RO + Ki67 + ) and the proximity of antigen-experienced cytotoxic T cells to melanoma cells were associated with positive response to ICIs. Our study highlights the potential of multiplexed single-cell technology to quantify spatial cell-cell interactions within the tumor microenvironment to understand immune therapy responses.


Related Papers